vimarsana.com
Home
Live Updates
REGENXBIO Reports Second Quarter 2022 Financial Results and
REGENXBIO Reports Second Quarter 2022 Financial Results and
REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
RGX-314 program for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, remains on track for first BLA filing in...
Related Keywords
United States ,
Cyprus ,
Dana Cormack ,
Eli Lilly ,
Chris Brinzey ,
Ultragenyx Pharmaceutical Inc ,
Technology Platform ,
Technology Platform Licensees ,
Rocket Pharmaceuticals Inc ,
Nasdaq ,
Novartis ,
Technology Licensee Program ,
Exchange Commission ,
Development Expenses ,
Therapeutics Inc ,
Corporate Communications ,
Securities Exchange ,
Manufacturing Innovation Center ,
Chief Executive Officer ,
Biologics Licensing Application ,
Duchenne Muscular Dystrophy ,
Mucopolysaccharidosis Type ,
Hunter Syndrome ,
Innovation Center ,
Licensee Program ,
Rocket Pharmaceuticals ,
Prevail Therapeutics Inc ,
Ultragenyx Pharmaceutical ,
Ornithine Transcarbamylase ,
Administrative Expenses ,
Platform Licensees ,
Securities Act ,
Securities Exchange Act ,
Financial Condition ,
Tax Benefit ,
Comprehensive Income ,
Regenxbio Inc ,